Cargando…

Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma

BACKGROUND: Less than 20% of melanoma patients respond to programmed cell death-1 (PD-1) blockade immunotherapies. Thus, it is crucial to understand the dynamic changes in the tumor microenvironment (TME) after PD-1 blockade, for developing immunotherapy efficacy. METHODS: A genomic analysis was con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Lili, Xu, Yu, Fang, Juemin, Liu, Weixing, Chen, Jianhua, Liu, Zhuqing, Xu, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082190/ https://www.ncbi.nlm.nih.gov/pubmed/33936081 http://dx.doi.org/10.3389/fimmu.2021.654749

Ejemplares similares

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells
por: Liu, Zhuqing, et al.
Publicado: (2017)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
por: Liu, Jian-Feng, et al.
Publicado: (2018)

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8(+) T cell dysfunction in melanoma patients
por: Fourcade, Julien, et al.
Publicado: (2010)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
por: Sun, Fan, et al.
Publicado: (2020)

STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
por: Shao, Xiaoyan, et al.
Publicado: (2019)

Tim‐3 blockade promotes iNKT cell function to inhibit HBV replication
por: Xu, Yong, et al.
Publicado: (2018)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice
por: Bitsch, Rebekka, et al.
Publicado: (2022)

Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
por: Wu, Zhengwei, et al.
Publicado: (2022)

Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells
por: Jiang, Wen, et al.
Publicado: (2022)

Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
por: Vackova, Julie, et al.
Publicado: (2020)

Targeting crosstalk of STAT3 between tumor-associated M2 macrophages and Tregs in colorectal cancer
por: Huang, Lili, et al.
Publicado: (2023)

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression
por: Yu, Muming, et al.
Publicado: (2017)

PD-1 and Tim-3 pathways are associated with regulatory CD8(+) T-cell function in decidua and maintenance of normal pregnancy
por: Wang, S-C, et al.
Publicado: (2015)

Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
por: Saleh, Reem, et al.
Publicado: (2020)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Ex vivo-expanded human CD19(+)TIM-1(+) regulatory B cells suppress immune responses in vivo and are dependent upon the TIM-1/STAT3 axis
por: Shankar, S., et al.
Publicado: (2022)

Tim-3 Expression Defines Regulatory T Cells in Human Tumors
por: Yan, Jing, et al.
Publicado: (2013)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells
por: Tripathi, Sudipta, et al.
Publicado: (2015)

Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8(+) antigen-specific T cells for adoptive immunotherapy
por: Lak, Shirin, et al.
Publicado: (2022)

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
por: Ju, Fei, et al.
Publicado: (2022)

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
por: Deken, Marcel A., et al.
Publicado: (2016)

EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo
por: Jensen, Katharine V, et al.
Publicado: (2020)

Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma
por: Ji, Xiang Lu, et al.
Publicado: (2019)

Supramolecular Photothermal Nanomedicine Mediated Distant Tumor Inhibition via PD-1 and TIM-3 Blockage
por: Huang, Tong-Yi, et al.
Publicado: (2020)

PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease
por: Duhalde Vega, Maite, et al.
Publicado: (2022)

Correlation of tumor‐infiltrating immune cells of melanoma with overall survival by immunogenomic analysis
por: Huang, Lili, et al.
Publicado: (2020)

IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2021)

Correction To: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Elevation of Tim-3 and PD-1 Expression on T Cells Appears Early in HIV Infection, and Differential Tim-3 and PD-1 Expression Patterns Can Be Induced by Common γ-Chain Cytokines
por: Zhang, Zi-Ning, et al.
Publicado: (2015)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

STAT6 Blockade Abrogates Aspergillus-Induced Eosinophilic Chronic Rhinosinusitis and Asthma, A Model of Unified Airway Disease
por: Sun, Hua, et al.
Publicado: (2022)

Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis
por: Choi, Yeon-Sook, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7v7qqp9rj9bq8198ru2f04hls9